washington, August 26, 2025 – At least 16 pharmaceutical companies are now altering their pricing strategies in response too new tariffs implemented by the United States, a move that underscores the escalating tension between global drugmakers and the Trump administration. The companies have agreed to reduce medicine prices in exchange for exemptions from the tariffs.
Trump’s Tariffs Reshape Pharma Pricing
The new tariff policy is prompting a important shift in how pharmaceutical companies approach pricing in the U.S. market.
- Last August, the European Union, under the leadership of Ursula von der Leyen, agreed to a 15 percent levy on goods from the Old Continent, including pharmaceuticals.
- President Trump introduced a “Most Favored Nation” (MFN) clause, allowing companies to avoid tariffs by lowering U.S. drug prices.
- Pfizer and AstraZeneca were among the first to concede, offering discounts of up to 80 percent on select medications through a new platform, TrumpRx.gov.
- As of early 2026, AbbVie and Johnson & Johnson joined the growing list of companies complying with the tariff agreement.
The tariffs, which became a reality last August, initially targeted a broad range of goods from the European Union. The agreement, led by Ursula von der Leyen, imposed levies of 15 percent on many products originating in Europe, including medications and vaccines.But President Trump had a strategic maneuver in play: the “Most Favored nation” (MFN) clause. This provision offered pharmaceutical companies a pathway to avoid the taxes – by lowering their drug prices within the United States.
What are the implications of the new tariff policy for American consumers? The policy aims to make prescription drugs more affordable for Americans by incentivizing companies to lower prices. These discounted drugs will be available on a special platform, TrumpRx.gov, designed as a central resource for accessing more affordable treatments.
The Pharmaceutical Companies That Have ‘Surrendered’ to Trump
The presidency of Donald Trump has directly impacted the European pharmaceutical industry, with companies and even specific drugs becoming targets. Even common pain relievers like paracetamol have been subject to debate. Though, the majority of the sector has opted to negotiate with the United States.
Last year, Donald Trump sent a letter to 17 pharmaceutical companies, demanding price reductions in exchange for tariff exemptions through the MFN clause. The companies included AbbVie, Boehringer Ingelheim, Bristol Myers Squibb, Novartis, Gilead, EMD Serono, Pfizer, Novo Nordisk, AstraZeneca, Amgen, Genentech, J&J, GSK, Merck, Regeneron, Sanofi, and Eli Lilly.
Pfizer was the first to respond, agreeing to lower prices. astrazeneca quickly followed, announcing plans to offer direct-to-consumer sales with discounts of up to 80 percent off list price, with its drugs also becoming available on TrumpRx.gov. Eli Lilly and Novo Nordisk also reached agreements with the administration. EMD Serono,a German subsidiary of Merck,also signed on for certain drugs in its portfolio.
By the end of december, nine additional companies – Bristol Myers Squibb, Genentech, Boehringer Ingelheim, Sanofi, Novartis, Merck, Gilead, GSK, and Amgen – had opted for tariff exemptions. In early 2026, Johnson & Johnson and AbbVie joined the list, completing the wave of concessions.
The relationship between the pharmaceutical industry and the United States has become increasingly focused on tariff policy. The MFN clause has now secured agreements with 16 companies, all aiming to avoid taxes through reduced drug prices in the U.S.
